Supplement sector silent on glucosamine data


Glucosamine is still being spruiked by the supplement industry as the answer to stiff and painful joints in people with osteoarthritis, despite evidence showing that it’s no better than placebo.

And with older Australians forking out up to $40 from their pension for a month’s supply, you’d think the vendors would have an obligation to show some proof of efficacy for this so-called building block of joint cartilage.

Not so, according to a group of Dutch researchers, who spent a fruitless